Starling Oncology, Inc. STLN
$6.94
$0.314.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 42.45% | 87.28% | 43.04% | -2.43% | -9.88% |
| Total Depreciation and Amortization | 1.83% | -9.42% | -4.39% | 9.54% | 18.91% |
| Total Amortization of Deferred Charges | 11.25% | -75.15% | -24.40% | -26.15% | -27.86% |
| Total Other Non-Cash Items | -39.44% | -172.31% | -81.17% | 209.70% | 4,940.85% |
| Change in Net Operating Assets | 535.31% | -70.34% | -39.90% | -153.84% | 3.55% |
| Cash from Operations | 217.04% | 55.59% | -22.77% | -1,642.12% | 34.85% |
| Capital Expenditure | 24.83% | -217.68% | 39.60% | -250.25% | 33.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 24.83% | -415.84% | 39.60% | -105.81% | -106.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -28.33% | 98.67% | -88.41% | -2,109.09% | -2,566.67% |
| Issuance of Common Stock | -95.91% | -98.44% | -- | -- | 110,050.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -111.11% | 99.41% | 2,376.83% | 4,462.14% | 191.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 214.47% | 66.92% | 160.56% | -123.99% | -2,660.16% |